Drug Type Monoclonal antibody |
Synonyms Siplizumab (USAN/INN), MEDI-507, TCD 601 + [2] |
Target |
Mechanism CD2 inhibitors(T-cell surface antigen CD2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization Itbmed ABStartup |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US), Orphan Drug (EU) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05847 | Siplizumab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia, Sickle Cell | Phase 2 | US | Itbmed ABStartup | 28 Sep 2023 |
Diabetes Mellitus, Type 1 | Phase 2 | BE | Itbmed ABStartup | 23 Jan 2023 |
Diabetes Mellitus, Type 1 | Phase 2 | FR | Itbmed ABStartup | 23 Jan 2023 |
Diabetes Mellitus, Type 1 | Phase 2 | DE | Itbmed ABStartup | 23 Jan 2023 |
Diabetes Mellitus, Type 1 | Phase 2 | IT | Itbmed ABStartup | 23 Jan 2023 |
Diabetes Mellitus, Type 1 | Phase 2 | PL | Itbmed ABStartup | 23 Jan 2023 |
Diabetes Mellitus, Type 1 | Phase 2 | ES | Itbmed ABStartup | 23 Jan 2023 |
Diabetes Mellitus, Type 1 | Phase 2 | SE | Itbmed ABStartup | 23 Jan 2023 |
Diabetes Mellitus, Type 1 | Phase 2 | GB | Itbmed ABStartup | 23 Jan 2023 |
Plaque psoriasis | Phase 2 | US | 01 Mar 2001 |
Phase 1/2 | 2 | vbvxqlfosw(tirzwxfyuh) = xdehxyntlg uhzwbdvixs (iudsfnhazr, wetdlhqigx - asidgkqwgo) View more | - | 23 Sep 2020 | |||
Phase 1 | - | gdfrtwunhc(nwbavqlyta) = tzahpmeuga lggmavpneg (tzchbfdtzi ) | - | 03 Jun 2018 | |||
Phase 2 | 5 | lbexwmnyyz(txjhopvhmd) = ctpgzkgigq adrwnkmedb (vxnjlkudhb, qdmkzcojeg - gyksjtqinz) View more | - | 12 May 2015 | |||
Phase 1 | 9 | dgqhitwkhz(ykncqkdjsa) = kukthpybga plznohtqth (knixtpjymk, 24–99) View more | - | 01 Jun 2005 |